MedTrace Logo

Study of Mood Effects of Varenicline (Chantix) in Depressed Outpatient Smokers

NCT00525837 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-11-28

Study results available
· View outcomes & findings →

Summary

This study will assess whether varenicline (chantix) has antidepressant properties when used in addition to other psychiatric medication. It will also assess whether varenicline improves the inability to feel pleasure (i.e. anhedonia), and if it is well-tolerated when used with psychiatric medications.

Enrolled patients will be assessed for improved mood, improved anhedonia, overall sense of health, side effects as well as tobacco use for 6-8 weeks.

Medication will be provided free of charge.

Conditions

  • Depressive Disorder
  • Smoking

Interventions

DRUG

fixed dose varenicline

varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.

DRUG

varenicline

up to 1 mg twice daily

Sponsors & Collaborators

  • Brown University

    collaborator OTHER

  • Butler Hospital

    lead OTHER

Principal Investigators

  • Noah S Philip, MD · Butler Hospital

  • Lawrence H Price, MD · Butler Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525837 on ClinicalTrials.gov